Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Itraconazole
Drug ID BADD_D01217
Description One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
Indications and Usage For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Marketing Status approved; investigational
ATC Code J02AC02
DrugBank ID DB01167
KEGG ID D00350
MeSH ID D017964
PubChem ID 55283
TTD Drug ID D0V4IB
NDC Product Code 22568-1108; 53069-0450; 59349-0012; 65015-624; 65162-630; 60592-318; 62991-3078; 72761-019; 50268-450; 50458-290; 10147-0150; 67835-5043; 46708-204; 49884-239; 60687-299; 49452-3845; 51552-0920; 70771-1208; 17511-114; 71747-002; 13668-463; 67877-454; 12578-299; 38779-2759; 58032-0110; 66039-815; 62332-204; 65162-087; 69339-159; 10147-1700; 71052-301; 70518-2872; 70518-3559; 10695-064; 50546-462; 31722-006; 51862-462; 68382-697; 70518-3264; 66577-044; 16714-743; 16729-271; 50458-295
UNII 304NUG5GF4
Synonyms Itraconazole | R-51211 | R 51211 | R51211 | Sporanox | Orungal
Chemical Information
Molecular Formula C35H38Cl2N8O4
CAS Registry Number 84625-61-6
SMILES CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C 7=C(C=C(C=C7)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrioventricular block02.03.01.0020.005345%-
Back pain15.03.04.005--
Bacteriuria11.02.01.014; 20.08.02.015---
Benign prostatic hyperplasia21.04.02.0010.004008%-
Bladder pain20.02.02.001---
Blindness transient06.02.10.006; 17.17.01.0040.002672%-
Blister12.01.06.002; 23.03.01.0010.005345%-
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
Blood triglycerides increased13.12.03.001---
Blood urea increased13.13.01.006---
Body temperature increased13.15.01.001---
Bradycardia02.03.02.0020.017370%-
Breast pain21.05.05.003--
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
Bursitis12.04.03.010; 15.04.01.001---
Cardiac arrest02.03.04.0010.018706%
Cardiac failure02.05.01.0010.062799%
Cardiac failure acute02.05.01.0050.004008%-
Cardiac failure congestive02.05.01.0020.024051%-
Cardiomegaly02.04.02.0010.004008%-
Cardiovascular disorder02.11.01.010; 24.03.02.0090.002672%-
Cerebrovascular disorder17.08.02.002; 24.03.05.0020.002672%-
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.0020.008017%-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Chills08.01.09.001; 15.05.03.016--
Cholestasis09.01.01.0010.013362%-
Chromaturia20.02.01.0020.004008%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 12 Pages